{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T01:47:19Z","timestamp":1771724839561,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,7,5]],"date-time":"2014-07-05T00:00:00Z","timestamp":1404518400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00228-014-1711-0","type":"journal-article","created":{"date-parts":[[2014,7,4]],"date-time":"2014-07-04T02:24:48Z","timestamp":1404440688000},"page":"1107-1113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol\/norethindrone"],"prefix":"10.1007","volume":"70","author":[{"given":"Wen H.","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa-Ping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig R.","family":"Shadle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan R.","family":"Butterton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,5]]},"reference":[{"key":"1711_CR1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.50.3.1013-1020.2006","volume":"50","author":"BA Malcolm","year":"2006","unstructured":"Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG (2006) SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 50:1013\u20131020","journal-title":"Antimicrob Agents Chemother"},{"key":"1711_CR2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy R, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki J-P (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195\u20131206","journal-title":"N Engl J Med"},{"key":"1711_CR3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"B Bacon","year":"2011","unstructured":"Bacon B, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Burroughs M, Brass CA, Albrecht JK, Esteban R (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207\u20131217","journal-title":"N Engl J Med"},{"key":"1711_CR4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.110.036996","volume":"39","author":"A Ghosal","year":"2011","unstructured":"Ghosal A, Yuan Y, Tong W, Su A, Gu C, Chowdhury SK, Kishnani NS (2011) Characterization of human liver enzymes involved in the biotransformation of boceprevir, a HCV protease inhibitor. Drug Metab Dispos 39:510\u2013521. doi: 10.1124\/dmd.110.036996","journal-title":"Drug Metab Dispos"},{"issue":"4 suppl","key":"1711_CR5","first-page":"140A","volume":"54","author":"X Chu","year":"2011","unstructured":"Chu X, Cai X, Cui D et al (2011) In vitro assessment of drug-drug interaction potential of boceprevir as an inhibitor and inducer of drug metabolizing enzymes and transporters. Hepatology 54(4 suppl):140A","journal-title":"Hepatology"},{"key":"1711_CR6","unstructured":"Schering-Plough (2009) Rebetol\u00ae (ribavirin UPS) capsules, oral solution. Schering Plough, Kenilworth, NJ"},{"key":"1711_CR7","unstructured":"Merck & Co., Inc. (2011) VICTRELIS\u2122 (boceprevir) Capsules. Merck & Co., Inc, Whitehouse Station, NJ"},{"key":"1711_CR8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/00003088-200443100-00003","volume":"43","author":"Z Yu","year":"2004","unstructured":"Yu Z, Yu D, Walker PS, Tang-Liu DD (2004) Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone\/ethinylestradiol oral contraceptive. Clin Pharmacokinet 43:673\u2013684","journal-title":"Clin Pharmacokinet"},{"key":"1711_CR9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1124\/dmd.104.000182","volume":"32","author":"B Wang","year":"2004","unstructured":"Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE (2004) The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos 32:1209\u20131212","journal-title":"Drug Metab Dispos"},{"key":"1711_CR10","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1177\/0091270011419855","volume":"52","author":"V Garg","year":"2012","unstructured":"Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N (2012) The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol 52:1574\u20131583. doi: 10.1177\/0091270011419855","journal-title":"J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1711-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1711-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1711-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:49:09Z","timestamp":1558702149000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1711-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,5]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1711-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,5]]}}}